{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:39:21Z","timestamp":1792741161124,"version":"4.5.0"},"reference-count":63,"publisher":"European Respiratory Society (ERS)","issue":"164","license":[{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2022,4,4]]},"published-print":{"date-parts":[[2022,6,30]]},"abstract":"<jats:p>Tuberculosis (TB) remains a leading infectious cause of death worldwide and the coronavirus disease 2019 pandemic has negatively impacted the global TB burden of disease indicators. If the targets of TB mortality and incidence reduction set by the international community are to be met, new more effective adult and adolescent TB vaccines are urgently needed. There are several new vaccine candidates at different stages of clinical development. Given the limited funding for vaccine development, it is crucial that trial designs are as efficient as possible. Prevention of infection (POI) approaches offer an attractive opportunity to accelerate new candidate vaccines to advance into large and expensive prevention of disease (POD) efficacy trials. However, POI approaches are limited by imperfect current tools to measure<jats:italic>Mycobacterium tuberculosis<\/jats:italic>infection end-points. POD trials need to carefully consider the type and number of microbiological tests that define TB disease and, if efficacy against subclinical (asymptomatic) TB disease is to be tested, POD trials need to explore how best to define and measure this form of TB. Prevention of recurrence trials are an alternative approach to generate proof of concept for efficacy, but optimal timing of vaccination relative to treatment must still be explored. Novel and efficient approaches to efficacy trial design, in addition to an increasing number of candidates entering phase 2\u20133 trials, would accelerate the long-standing quest for a new TB vaccine.<\/jats:p>","DOI":"10.1183\/16000617.0044-2022","type":"journal-article","created":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T07:55:14Z","timestamp":1654674914000},"page":"220044","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["End-point definition and trial design to advance tuberculosis vaccine development"],"prefix":"10.1183","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2038-5505","authenticated-orcid":false,"given":"Alberto L.","family":"Garcia-Basteiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dereck","family":"Tait","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander C.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molebogeng X.","family":"Rangaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Quaife","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1662-4961","authenticated-orcid":false,"given":"Elisa","family":"Nemes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Mogg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip C.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca C.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem A.","family":"Hanekom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Frick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7627-2166","authenticated-orcid":false,"given":"Andrew","family":"Fiore-Gartland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4181-058X","authenticated-orcid":false,"given":"Alemnew F.","family":"Dagnew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Churchyard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Cobelens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel A.","family":"Behr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hatherill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2022,6,7]]},"reference":[{"key":"2024102404041448000_31.164.220044.1","unstructured":"World Health Organization . Global Tuberculosis Report 2021. Geneva, Switzerland , 2021. Available from: www.who.int\/publications\/i\/item\/9789240037021"},{"key":"2024102404041448000_31.164.220044.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00403-5"},{"key":"2024102404041448000_31.164.220044.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60570-0"},{"key":"2024102404041448000_31.164.220044.4","unstructured":"Tuberculosis Vaccine Initiative (TBVI) . Pipeline of Vaccines. 2021. Available from: www.tbvi.eu\/what-we-do\/pipeline-of-vaccines\/ Date last accessed: 7 February 2022."},{"key":"2024102404041448000_31.164.220044.5","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1080\/14760584.2016.1178067","article-title":"Design of tuberculosis vaccine trials under financial constraints","volume":"15","author":"Garc\u00eda-Basteiro","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"2024102404041448000_31.164.220044.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714021"},{"key":"2024102404041448000_31.164.220044.7","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-10-37"},{"key":"2024102404041448000_31.164.220044.8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k2738"},{"key":"2024102404041448000_31.164.220044.9","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201206-1134OC"},{"key":"2024102404041448000_31.164.220044.10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007305"},{"key":"2024102404041448000_31.164.220044.11","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir951"},{"key":"2024102404041448000_31.164.220044.12","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax4607"},{"key":"2024102404041448000_31.164.220044.13","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00034-13"},{"key":"2024102404041448000_31.164.220044.14","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S2213-2600(17)30060-7","article-title":"Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study","volume":"5","author":"Andrews","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2024102404041448000_31.164.220044.15","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1164\/rccm.201905-0969OC","article-title":"Quantitative IFN-\u03b3 release assay and tuberculin skin test results to predict incident tuberculosis. A prospective cohort study","volume":"201","author":"Gupta","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102404041448000_31.164.220044.16","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.ijid.2019.01.048","article-title":"Tuberculin skin test \u2013 Outdated or still useful for latent TB infection screening?","volume":"80","author":"Gualano","year":"2019","journal-title":"Int J Infect Dis"},{"key":"2024102404041448000_31.164.220044.17","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201704-0817OC"},{"key":"2024102404041448000_31.164.220044.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01316-1"},{"key":"2024102404041448000_31.164.220044.19","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1164\/rccm.201711-2340OC","article-title":"Four-gene pan-African blood signature predicts progression to tuberculosis","volume":"197","author":"Suliman","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102404041448000_31.164.220044.20","doi-asserted-by":"crossref","first-page":"e841","DOI":"10.1016\/S2214-109X(21)00045-0","article-title":"Validation of a host blood transcriptomic biomarker for pulmonary tuberculosis in people living with HIV: a prospective diagnostic and prognostic accuracy study","volume":"9","author":"Mendelsohn","year":"2021","journal-title":"Lancet Glob Heal"},{"key":"2024102404041448000_31.164.220044.21","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S2213-2600(19)30282-6","article-title":"Concise whole blood transcriptional signatures for incipient tuberculosis: a systematic review and patient-level pooled meta-analysis","volume":"8","author":"Gupta","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2024102404041448000_31.164.220044.22","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201409-1704OC"},{"key":"2024102404041448000_31.164.220044.23","doi-asserted-by":"crossref","first-page":"15626","DOI":"10.1038\/s41598-018-33825-w","article-title":"Effect of therapy on Quantiferon-Plus response in patients with active and latent tuberculosis infection","volume":"8","author":"Petruccioli","year":"2018","journal-title":"Sci Rep"},{"key":"2024102404041448000_31.164.220044.24","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.00021-14"},{"key":"2024102404041448000_31.164.220044.25","doi-asserted-by":"crossref","first-page":"7239","DOI":"10.1016\/j.vaccine.2020.09.055","article-title":"DAR-901 vaccine for the prevention of infection with Mycobacterium tuberculosis among BCG-immunized adolescents in Tanzania: a randomized controlled, double-blind phase 2b trial","volume":"38","author":"Munseri","year":"2020","journal-title":"Vaccine"},{"key":"2024102404041448000_31.164.220044.26","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0441-3"},{"key":"2024102404041448000_31.164.220044.27","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3389\/fimmu.2021.619988","article-title":"Phenotype definition for \u201cResisters\u201d to Mycobacterium tuberculosis infection in the literature\u2014A review and recommendations","volume":"12","author":"Gutierrez","year":"2021","journal-title":"Front Immunol"},{"key":"2024102404041448000_31.164.220044.28","first-page":"15770","article-title":"Is Mycobacterium tuberculosis infection life long?","volume":"367","author":"Behr","year":"2019","journal-title":"BMJ"},{"key":"2024102404041448000_31.164.220044.29","doi-asserted-by":"crossref","first-page":"20201635","DOI":"10.1098\/rspb.2020.1635","article-title":"Self-clearance of Mycobacterium tuberculosis infection: implications for lifetime risk and population at-risk of tuberculosis disease","volume":"288","author":"Emery","year":"2021","journal-title":"Proc R Soc B Biol Sci"},{"key":"2024102404041448000_31.164.220044.30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002152"},{"key":"2024102404041448000_31.164.220044.31","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1164\/rccm.202011-4239PP","article-title":"Latent tuberculosis: two centuries of confusion","volume":"204","author":"Behr","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102404041448000_31.164.220044.32","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/cid\/ciz034","article-title":"Diagnostic accuracy of early secretory antigenic target-6-free interferon-gamma release assay compared to QuantiFERON-TB gold in-tube","volume":"69","author":"Nemes","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2024102404041448000_31.164.220044.33","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00021-18"},{"key":"2024102404041448000_31.164.220044.34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803484"},{"key":"2024102404041448000_31.164.220044.35","unstructured":"van der Walt M , Moyo S , et al. The First National TB Prevalence Survey. South Africa, 2018. https:\/\/www.nicd.ac.za\/wp-content\/uploads\/2021\/02\/TB-Prevalence-survey-report_A4_SA_TPS-Short_Feb-2021.pdf Date last accessed: 4 May 2021."},{"key":"2024102404041448000_31.164.220044.36","unstructured":"World Health Organization . WHO consolidated guidelines on tuberculosis module 2: screening \u2013 systematic screening for tuberculosis disease. Geneva, Switzerland . 2021. https:\/\/www.who.int\/publications\/i\/item\/9789240022676"},{"key":"2024102404041448000_31.164.220044.37","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1093\/cid\/ciab639","article-title":"Chest X-ray analysis with deep learning-based software as a triage test for pulmonary tuberculosis: an individual patient data meta-analysis of diagnostic accuracy","volume":"74","author":"Tavaziva","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2024102404041448000_31.164.220044.38","unstructured":"World Health Organization . Same-day diagnosis of tuberculosis by microscopy. Policy Statement. 2011. http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/44603\/9789241501606_eng.pdf?sequence=1 Date last accessed: 30 July 2021."},{"key":"2024102404041448000_31.164.220044.39","first-page":"CD009593","article-title":"Xpert Ultra versus Xpert MTB\/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis","volume":"2","author":"Zifodya","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"2024102404041448000_31.164.220044.40","first-page":"1016","article-title":"Use of simulated sputum specimens to estimate the specificity of laboratory-diagnosed tuberculosis","volume":"14","author":"Demers","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024102404041448000_31.164.220044.41","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2006.104976"},{"key":"2024102404041448000_31.164.220044.42","doi-asserted-by":"publisher","DOI":"10.1086\/502652"},{"key":"2024102404041448000_31.164.220044.43","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ581"},{"key":"2024102404041448000_31.164.220044.44","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit790"},{"key":"2024102404041448000_31.164.220044.45","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0041-3879(82)80006-8","article-title":"Retrospective assessment of the effectiveness of BCG vaccination against tuberculosis using the case-control method","volume":"63","author":"Smith","year":"1982","journal-title":"Tubercle"},{"key":"2024102404041448000_31.164.220044.46","doi-asserted-by":"publisher","DOI":"10.3310\/hta17370"},{"key":"2024102404041448000_31.164.220044.47","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.03154"},{"key":"2024102404041448000_31.164.220044.48","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.tube.2015.02.036","article-title":"Innovative clinical trial designs to rationalize TB vaccine development","volume":"95","author":"Ellis","year":"2015","journal-title":"Tuberculosis"},{"key":"2024102404041448000_31.164.220044.49","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1093\/cid\/ciaa470","article-title":"High rates of recurrent tuberculosis disease: a population-level cohort study","volume":"72","author":"Hermans","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024102404041448000_31.164.220044.50","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.3389\/fmicb.2016.01536","article-title":"The progress of therapeutic vaccination with regard to tuberculosis","volume":"7","author":"Cardona","year":"2016","journal-title":"Front Microbiol"},{"key":"2024102404041448000_31.164.220044.51","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4177"},{"key":"2024102404041448000_31.164.220044.52","doi-asserted-by":"crossref","first-page":"9","DOI":"10.12688\/gatesopenres.12750.1","article-title":"Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trial","volume":"1","author":"Chen","year":"2017","journal-title":"Gates Open Res"},{"key":"2024102404041448000_31.164.220044.53","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.vaccine.2019.10.072","article-title":"Preferred product characteristics for therapeutic vaccines to improve tuberculosis treatment outcomes: key considerations from World Health Organization consultations","volume":"38","author":"Vekemans","year":"2020","journal-title":"Vaccine"},{"key":"2024102404041448000_31.164.220044.54","doi-asserted-by":"publisher","DOI":"10.1086\/651492"},{"key":"2024102404041448000_31.164.220044.55","unstructured":"World Health Organization . Latent TB Infection: Updated and consolidated guidelines for programmatic management. Geneva, Switzerland , 2018. https:\/\/www.who.int\/publications\/i\/item\/9789241550239"},{"key":"2024102404041448000_31.164.220044.56","doi-asserted-by":"publisher","DOI":"10.1086\/506432"},{"key":"2024102404041448000_31.164.220044.57","doi-asserted-by":"crossref","first-page":"e830","DOI":"10.1093\/cid\/ciaa1402","article-title":"Subclinical tuberculosis disease-a review and analysis of prevalence surveys to inform definitions, burden, associations, and screening methodology","volume":"73","author":"Frascella","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024102404041448000_31.164.220044.58","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12916-017-0822-8","article-title":"Diagnostic accuracy, incremental yield and prognostic value of determine TB-LAM for routine diagnostic testing for tuberculosis in HIV-infected patients requiring acute hospital admission in South Africa: a prospective cohort","volume":"15","author":"Lawn","year":"2017","journal-title":"BMC Med"},{"key":"2024102404041448000_31.164.220044.59","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70251-1"},{"key":"2024102404041448000_31.164.220044.60","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1473-3099(19)30001-5","article-title":"Novel lipoarabinomannan point-of-care tuberculosis test for people with HIV: a diagnostic accuracy study","volume":"19","author":"Broger","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2024102404041448000_31.164.220044.61","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00042-10"},{"key":"2024102404041448000_31.164.220044.62","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.12.0737"},{"key":"2024102404041448000_31.164.220044.63","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104875"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0044-2022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:05:07Z","timestamp":1740373507000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0044-2022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,7]]},"references-count":63,"journal-issue":{"issue":"164","published-online":{"date-parts":[[2022,6,7]]},"published-print":{"date-parts":[[2022,6,30]]}},"alternative-id":["10.1183\/16000617.0044-2022"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0044-2022","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,7]]}}}